Latest Update on Metformin

Buy Lab Tests Online

mcs

Member
Observations being on ER-Metformin for last 4.5 mos.
(started July 1, 2022)
  1. 15lbs weight loss - no change in diet or training
  2. No GI problems up to 2g/day
  3. No change in fasting glucose levels or a1c (not diabetic to begin with)
  4. *Substantial decrease in total and free T (not on TRT):
    • June, 2022 (pre-Metformin): TT: 553; FT: 76.9
    • August, 2022 (1 month Metformin): TT: 415; FT: 70.2
    • November, 2022 (4 months Metformin): TT: 318; FT: 61.7
  5. No difference in aerobic or resistance training
  6. Slight decrease in IGF-1 (which I don't mind because mine was already high normal @ 250)
  7. B12 is still over range (because I supplement with 1-2mg/day!)
*I was always on the fence about TRT but now since the Metformin has tanked my levels, maybe this is the push I need? The only problem is I have hypertension and had clotting issues in the past, both of which I'm managing with meds (telmisartan, nebivolol, rivaroxaban), but the hypertension is on the top of my list of TRT side effects and BP is still not where I'd like to see it (120/80 or less). 62 y/o male.

Thoughts?
 
Last edited:
Defy Medical TRT clinic doctor

Vince

Super Moderator
Observations being on ER-Metformin for last 4.5 mos.
(started July 1, 2022)
  1. 15lbs weight loss - no change in diet or training
  2. No GI problems up to 2g/day
  3. No change in fasting glucose levels or a1c (not diabetic to begin with)
  4. *Substantial decrease in total and free T (not on TRT):
    • June, 2022 (pre-Metformin): TT: 553; FT: 76.9
    • August, 2022 (1 month Metformin): TT: 415; FT: 70.2
    • November, 2022 (4 months Metformin): TT: 318; FT: 61.7
  5. No difference in aerobic or resistance training
  6. Slight decrease in IGF-1 (which I don't mind because mine was already high normal @ 250)
  7. B12 is still over range (because I supplement with 1-2mg/day!)
*I was always on the fence about TRT but now since the Metformin has tanked my levels, maybe this is the push I need? The only problem is I have hypertension and had clotting issues in the past, both of which I'm managing with meds (telmisartan, nebivolol, rivaroxaban), but the hypertension is on the top of my list of TRT side effects and BP is still not where I'd like to see it (120/80 or less). 62 y/o male.

Thoughts?
What is your fasting? Glucose and your A1C.
 

Nelson Vergel

Founder, ExcelMale.com
Thanks for the detailed encouraging report. If you have BP issues, TRT may be a problem.

How much do you weigh now and how tall are you ?

Have you had genetic testing for the clotting issue ?
 

mcs

Member
What is your fasting? Glucose and your A1C.
low 100s if I don't fast for at least 12h, in the mid to high 90s if I do. If I eat even complex carbs for dinner, FBG will go into the 110-115. A1C 4.9-5.2. Metformin doesn't seem to influence those numbers either way. I take 1g with last meal and 500mg before sleep.
 
Last edited:

mcs

Member
Thanks for the detailed encouraging report. If you have BP issues, TRT may be a problem.

How much do you weigh now and how tall are you ?

Have you had genetic testing for the clotting issue ?
5-7 180lbs - but even when I weighed 20lbs less, my BP did not lessen.
Have tested my DNA extensively for hereditary clotting issues and nothing came up except MTHFR. I feel I need be on TRT at this point and think I should d/c the Metformin for now until my T levels are optimized. Maybe start with low-dose of T like 30mg EOD (112.5mg/week)?
 
Last edited:

Vince

Super Moderator
low 100s if I don't fast for at least 12h, in the mid to high 90s if I do. If I eat even complex carbs for dinner, FBG will go into the 110-115. A1C 4.9-5.2. Metformin doesn't seem to influence those numbers either way. I take 1g with last meal and 500mg before sleep.
Does your labs tell your average glucose reading?
 

mcs

Member
Does your labs tell your average glucose reading?
My glucometer app does:


1668901911085.png
 

mcs

Member
My joint pains have worsened to which I attribute both low T and E2 symptoms. I think it's obvious I should d/c the Metformin until I get my hormones optimized.
 

BigTex

Well-Known Member
Observations being on ER-Metformin for last 4.5 mos.
(started July 1, 2022)
  1. 15lbs weight loss - no change in diet or training
  2. No GI problems up to 2g/day
  3. No change in fasting glucose levels or a1c (not diabetic to begin with)
  4. *Substantial decrease in total and free T (not on TRT):
    • June, 2022 (pre-Metformin): TT: 553; FT: 76.9
    • August, 2022 (1 month Metformin): TT: 415; FT: 70.2
    • November, 2022 (4 months Metformin): TT: 318; FT: 61.7
  5. No difference in aerobic or resistance training
  6. Slight decrease in IGF-1 (which I don't mind because mine was already high normal @ 250)
  7. B12 is still over range (because I supplement with 1-2mg/day!)
*I was always on the fence about TRT but now since the Metformin has tanked my levels, maybe this is the push I need? The only problem is I have hypertension and had clotting issues in the past, both of which I'm managing with meds (telmisartan, nebivolol, rivaroxaban), but the hypertension is on the top of my list of TRT side effects and BP is still not where I'd like to see it (120/80 or less). 62 y/o male.

Thoughts?
Here is some material to read over
 

Biobro

Member

Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system​



Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges​


Conclusions​

Several works recently suggested that metformin may be used as a promising therapeutic strategy to counteract the progression of neurodegenerative disorders, including PD. However, despite intensive research, the precise mechanisms by which metformin exerts its activity are not completely understood. Therefore, to determine the potential therapeutic use of metformin as a disease modifier for PD, it is crucial to evaluate its main pharmacological properties, such as the bioavailability in the brain, the molecular pathways it affects, and the concentrations necessary to observe the beneficial effects. Unfortunately, the data available in the literature are often controversial and vary significantly among experimental models, prompting the necessity to outline a consensus in pre-clinical data interpretation.

At the same time, the prolonged consumption of metformin at a relatively high dosage might induce serious side effects that could worsen the risk of developing PD over time. In this frame, the epidemiological studies that investigated the association between metformin therapy and PD only assessed the effect of the drug in T2DM patients [65,66,67,68,69].

Hypothesis: Metformin is a potential reproductive toxicant​



Metformin Linked to More Severe Neuropathy Pain​

 
Last edited:

BigTex

Well-Known Member
Thanks for posting this @Bibro. Very interesting stuff. By the way, I use it off and on. I have to eat a huge amount of calories to keep my weight but when I take metformin the weight comes off quickly. So I have to be careful how long I am on it.
 

Biobro

Member
Thanks for posting this @Bibro. Very interesting stuff. By the way, I use it off and on. I have to eat a huge amount of calories to keep my weight but when I take metformin the weight comes off quickly. So I have to be careful how long I am on it.
Gotcha! Does it give you any side effects?
I’ve been playing around 500mg ER dosages once daily lately. Makes me too relaxed, lazy and gives me constipation.
And because of the studies i dont think im gonna continue that experiment anymore.
Far better alternatives out there, example semaglutide.
 

Biobro

Member
I use it for longevity benefits.
And you probably know that those longevity benefits has been repealed on high risk type 2 diabetes patients and placebo in latest studies. But of course it preventing you becoming type 2 diabetic.

Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study​

Christine G Lee et al. Diabetes Care. 2021 Dec.

Abstract​

Objective: To determine whether metformin or lifestyle modification can lower rates of all-cause and cause-specific mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.
Research design and methods: From 1996 to 1999, 3,234 adults at high risk for type 2 diabetes were randomized to an intensive lifestyle intervention, masked metformin, or placebo. Placebo and lifestyle interventions stopped in 2001, and a modified lifestyle program was offered to everyone, but unmasked study metformin continued in those originally randomized. Causes of deaths through 31 December 2018 were adjudicated by blinded reviews. All-cause and cause-specific mortality hazard ratios (HRs) were estimated from Cox proportional hazards regression models and Fine-Gray models, respectively.
Results: Over a median of 21 years (interquartile range 20-21), 453 participants died. Cancer was the leading cause of death (n = 170), followed by cardiovascular disease (n = 131). Compared with placebo, metformin did not influence mortality from all causes (HR 0.99 [95% CI 0.79, 1.25]), cancer (HR 1.04 [95% CI 0.72, 1.52]), or cardiovascular disease (HR 1.08 [95% CI 0.70, 1.66]). Similarly, lifestyle modification did not impact all-cause (HR 1.02 [95% CI 0.81, 1.28]), cancer (HR 1.07 [95% CI 0.74, 1.55]), or cardiovascular disease (HR 1.18 [95% CI 0.77, 1.81]) mortality. Analyses adjusted for diabetes status and duration, BMI, cumulative glycemic exposure, and cardiovascular risks yielded results similar to those for all-cause mortality.
Conclusions: Cancer was the leading cause of mortality among adults at high risk for type 2 diabetes. Although metformin and lifestyle modification prevented diabetes, neither strategy reduced all-cause, cancer, or cardiovascular mortality rates.


Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study​

Originally published 23 May 2022

Background:​

Lifestyle intervention and metformin have been shown to prevent diabetes; however, their efficacy in preventing cardiovascular disease associated with the development of diabetes is unclear. We examined whether these interventions reduced the incidence of major cardiovascular events over a 21-year median follow-up of participants in the DPP trial (Diabetes Prevention Program) and DPPOS (Diabetes Prevention Program Outcomes Study).


Methods:​

During DPP, 3234 participants with impaired glucose tolerance were randomly assigned to metformin 850 mg twice daily, intensive lifestyle or placebo, and followed for 3 years. During the next 18-year average follow-up in DPPOS, all participants were offered a less intensive group lifestyle intervention, and unmasked metformin was continued in the metformin group. The primary outcome was the first occurrence of nonfatal myocardial infarction, stroke, or cardiovascular death adjudicated by standard criteria. An extended cardiovascular outcome included the primary outcome or hospitalization for heart failure or unstable angina, coronary or peripheral revascularization, coronary heart disease diagnosed by angiography, or silent myocardial infarction by ECG. ECGs and cardiovascular risk factors were measured annually.


Results:​

Neither metformin nor lifestyle intervention reduced the primary outcome: metformin versus placebo hazard ratio 1.03 (95% CI, 0.78–1.37; P= 0.81) and lifestyle versus placebo hazard ratio 1.14 (95% CI, 0.87–1.50; P = 0.34). Risk factor adjustment did not change these results. No effect of either intervention was seen on the extended cardiovascular outcome.


Conclusions:​

Neither metformin nor lifestyle reduced major cardiovascular events in DPPOS over 21 years despite long-term prevention of diabetes. Provision of group lifestyle intervention to all, extensive out-of-study use of statin and antihypertensive agents, and reduction in the use of study metformin together with out-of-study metformin use over time may have diluted the effects of the interventions.


 
Last edited:

Vince

Super Moderator
And you probably know that those longevity benefits has been repealed on high risk type 2 diabetes patients and placebo in latest studies. But of course it preventing you becoming type 2 diabetic.

Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study​

Christine G Lee et al. Diabetes Care. 2021 Dec.

Abstract​

Objective: To determine whether metformin or lifestyle modification can lower rates of all-cause and cause-specific mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.
Research design and methods: From 1996 to 1999, 3,234 adults at high risk for type 2 diabetes were randomized to an intensive lifestyle intervention, masked metformin, or placebo. Placebo and lifestyle interventions stopped in 2001, and a modified lifestyle program was offered to everyone, but unmasked study metformin continued in those originally randomized. Causes of deaths through 31 December 2018 were adjudicated by blinded reviews. All-cause and cause-specific mortality hazard ratios (HRs) were estimated from Cox proportional hazards regression models and Fine-Gray models, respectively.
Results: Over a median of 21 years (interquartile range 20-21), 453 participants died. Cancer was the leading cause of death (n = 170), followed by cardiovascular disease (n = 131). Compared with placebo, metformin did not influence mortality from all causes (HR 0.99 [95% CI 0.79, 1.25]), cancer (HR 1.04 [95% CI 0.72, 1.52]), or cardiovascular disease (HR 1.08 [95% CI 0.70, 1.66]). Similarly, lifestyle modification did not impact all-cause (HR 1.02 [95% CI 0.81, 1.28]), cancer (HR 1.07 [95% CI 0.74, 1.55]), or cardiovascular disease (HR 1.18 [95% CI 0.77, 1.81]) mortality. Analyses adjusted for diabetes status and duration, BMI, cumulative glycemic exposure, and cardiovascular risks yielded results similar to those for all-cause mortality.
Conclusions: Cancer was the leading cause of mortality among adults at high risk for type 2 diabetes. Although metformin and lifestyle modification prevented diabetes, neither strategy reduced all-cause, cancer, or cardiovascular mortality rates.


Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study​

Originally published 23 May 2022

Background:​

Lifestyle intervention and metformin have been shown to prevent diabetes; however, their efficacy in preventing cardiovascular disease associated with the development of diabetes is unclear. We examined whether these interventions reduced the incidence of major cardiovascular events over a 21-year median follow-up of participants in the DPP trial (Diabetes Prevention Program) and DPPOS (Diabetes Prevention Program Outcomes Study).


Methods:​

During DPP, 3234 participants with impaired glucose tolerance were randomly assigned to metformin 850 mg twice daily, intensive lifestyle or placebo, and followed for 3 years. During the next 18-year average follow-up in DPPOS, all participants were offered a less intensive group lifestyle intervention, and unmasked metformin was continued in the metformin group. The primary outcome was the first occurrence of nonfatal myocardial infarction, stroke, or cardiovascular death adjudicated by standard criteria. An extended cardiovascular outcome included the primary outcome or hospitalization for heart failure or unstable angina, coronary or peripheral revascularization, coronary heart disease diagnosed by angiography, or silent myocardial infarction by ECG. ECGs and cardiovascular risk factors were measured annually.


Results:​

Neither metformin nor lifestyle intervention reduced the primary outcome: metformin versus placebo hazard ratio 1.03 (95% CI, 0.78–1.37; P= 0.81) and lifestyle versus placebo hazard ratio 1.14 (95% CI, 0.87–1.50; P = 0.34). Risk factor adjustment did not change these results. No effect of either intervention was seen on the extended cardiovascular outcome.


Conclusions:​

Neither metformin nor lifestyle reduced major cardiovascular events in DPPOS over 21 years despite long-term prevention of diabetes. Provision of group lifestyle intervention to all, extensive out-of-study use of statin and antihypertensive agents, and reduction in the use of study metformin together with out-of-study metformin use over time may have diluted the effects of the interventions.


My understanding is if you have type 2 diabetes and use metformin you have better longitivity, then someone who is not type 2 diabetic and does not use metformin.
 

Biobro

Member
My understanding is if you have type 2 diabetes and use metformin you have better longitivity, then someone who is not type 2 diabetic and does not use metformin.
You probably mean this study. Yes if you already have type 2 diabetes,
But if you are high risk patient or non risk patient you get no longevity benefits.


Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls​

Conclusions: Patients with type 2 diabetes initiated with metformin monotherapy had longer survival than did matched, non-diabetic controls.

 

Vince

Super Moderator
You probably mean this study. Yes if you already have type 2 diabetes,
But if you are high risk patient or non diabetic you get no longevity benefits.


Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls​

Conclusions: Patients with type 2 diabetes initiated with metformin monotherapy had longer survival than did matched, non-diabetic controls.

I think the main benefit for everyone should be diets that do not spike your insulate levels. Which is of course low carb.

I almost forgot to mention, diet soda will turn you into a type 2 diabetic.
 
Buy Lab Tests Online
Defy Medical TRT clinic

Sponsors

enclomiphene
nelson vergel coaching for men
Discounted Labs
TRT in UK Balance my hormones
Testosterone books nelson vergel
Register on ExcelMale.com
Trimix HCG Offer Excelmale
Thumos USA men's mentoring and coaching
Testosterone TRT HRT Doctor Near Me

Online statistics

Members online
5
Guests online
4
Total visitors
9

Latest posts

bodybuilder test discounted labs
Top